Open original FDA record ↗Recall record
- FDA identifier
- Z-0992-2024
- Company in FDA record
- Randox Laboratories Ltd.
- FDA classification date
- Feb 6, 2024
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Randox Laboratories have released an update to the Carryover Avoidance Technical Bulletin to detail that Copper, should not be run directly after Total Protein, on the RX series instruments testing order. If copper assay is run after total protein it could lead to falsely elevated copper results.
Source facts
- Action
- RANDOX Distributors issued Medical Device Correction Letter (REC704) on December 12, 2023 to US consignees. Letter states reason for recall, health risk and action to take: Review your instrument testing order in line with the Carryover Avoidance Technical Bulletin (RXTB-0148) " Update the RX user manual with the updated Carryover Avoidance Technical Bulletin (RXTB-0148) and ensure all operators are aware of the recommendations. " Discuss the contents of this notice with your Medical Director. " Complete and return the response form 12187-QA to technical.services@randox.com within five working days. Transmission of Field Safety Notice: Send a copy of the FSN to all affected customers and to those who need to be aware within your organization.
- Initiated
- 2023-11-29
- Root cause
- Component design/selection
- Distribution
- US Nationwide distribution in the states of SC and OK.
- Recall number
- Z-0992-2024
- Recall status
- Open, Classified
- CDRH record ID
- 205416
- FDA classified
- 2024-02-06
- Recall event number
- 93775